Literature DB >> 9326391

A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis.

T Höhler1, A Kruger, P M Schneider, R E Schopf, J Knop, C Rittner, K H Meyer zum Büschenfelde, E Märker-Hermann.   

Abstract

Tumor necrosis factor-alpha is considered to be one of the important mediators in the pathogenesis of psoriasis. A strong association of juvenile onset psoriasis with the major histocompatibility complex encoded HLA-Cw6 antigen has been reported but it is unclear whether Cw6 itself or a closely linked gene is involved in the pathogenesis. This study has focused on the association of promoter polymorphisms of the major histocompatibility complex encoded tumor necrosis factor-alpha gene with psoriasis and psoriatic arthritis. Tumor necrosis factor-alpha promoter polymorphisms were sought by sequence-specific oligonucleotide hybridization and by direct sequencing in Caucasian patients with juvenile onset psoriasis and with psoriatic arthritis and in healthy controls. A mutation at position -238 of the tumor necrosis factor-alpha promoter was present in 23 of 60 patients (38%; p < 0.0001; p[corr] < 0.008) with juvenile onset psoriasis and in 20 of 62 patients (32%; p < 0.0003; p[corr] < 0.03) with psoriatic arthritis, compared with seven of 99 (7%) Caucasian controls. There was a marked increase of homozygotes for this mutation in the psoriasis group. Another mutation at position -308 was found in similar proportions of patients and controls. Our study shows a strong association of the tumor necrosis factor-alpha promoter polymorphism at position -238 with psoriasis and psoriatic arthritis. Our findings suggest that this promoter polymorphism itself or a gene in linkage disequilibrium with tumor necrosis factor-alpha predispose to the development of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326391     DOI: 10.1111/1523-1747.ep12337469

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  31 in total

Review 1.  Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis.

Authors:  C L Verweij
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

Review 3.  Disease mechanisms in psoriasis and psoriatic arthritis.

Authors:  P Costello; O FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

4.  Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

Authors:  A Kavanaugh; G G Krueger; A Beutler; C Guzzo; B Zhou; L T Dooley; P J Mease; D D Gladman; K de Vlam; P P Geusens; C Birbara; D G Halter; C Antoni
Journal:  Ann Rheum Dis       Date:  2006-11-17       Impact factor: 19.103

Review 5.  Seronegative spondyloarthropathies: to lump or split?

Authors:  P Nash; P J Mease; J Braun; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

Review 6.  [Psoriatic arthritis : a permanent challenge for rheumatologists and patients--Part 1: epidemiology, pathogenesis and clinical course].

Authors:  S Finzel; M Englbrecht
Journal:  Z Rheumatol       Date:  2011-10       Impact factor: 1.372

7.  Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis.

Authors:  E L Kaijzel; M V van Krugten; B M Brinkman; T W Huizinga; T van der Straaten; J M Hazes; H W Ziegler-Heitbrock; S A Nedospasov; F C Breedveld; C L Verweij
Journal:  Mol Med       Date:  1998-11       Impact factor: 6.354

Review 8.  Psoriasis: a complex clinical and genetic disorder.

Authors:  Helgi Valdimarsson; Ari Karason; Johann E Gudjonsson
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

Review 9.  Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.

Authors:  David Kane; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

10.  Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.

Authors:  Jochen Schmitt; Gottfried Wozel
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.